Tirzepatide for diabetes: on track to SURPASS current therapy
- PMID: 35260841
- DOI: 10.1038/s41591-022-01733-2
Tirzepatide for diabetes: on track to SURPASS current therapy
Comment on
-
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.Nat Med. 2022 Mar;28(3):591-598. doi: 10.1038/s41591-022-01707-4. Epub 2022 Feb 24. Nat Med. 2022. PMID: 35210595 Free PMC article.
References
-
- McMurray, J. J. V. et al. N. Engl. J. Med. 381, 1995–2008 (2019). - DOI
-
- Anker, S. D. et al. N. Engl. J. Med. 385, 1451–1461 (2021). - DOI
-
- Marso, S. P. et al. N. Engl. J. Med. 375, 1834–1844 (2016). - DOI
-
- Gerstein, H. C. et al. Lancet 394, 121–130 (2019). - DOI
-
- Frías, J. P. et al. N. Engl. J. Med. 385, 503–515 (2021). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
